Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia (Q61774244)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

title

Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Carmelo Carlo-Stella

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Marco Ruella

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Rosalba Miceli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Liliana Devizzi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Arianna Giacomini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Maria Adele Testi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Luigi Mariani

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Massimo Di Nicola

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Roberto Passera

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Stefano Buttiglieri

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Alessandra Risso

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Corrado Tarella

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Silvia L Locatelli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

Alessandro M Gianni

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

language of work or name

English

0 references

publication date

12 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

issue

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

5074-5084

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

Stem cell transplantation for non-Hodgkin's lymphoma

31 January 2020

cites work

1 reference

7 January 2021

Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.

1 reference

7 January 2021

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

7 January 2021

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 B-cell lymphoma: long-term follow-up of a phase 1/2 study

1 reference

7 January 2021

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

7 January 2021

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

7 January 2021

Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma

1 reference

7 January 2021

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma

1 reference

7 January 2021

Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas

1 reference

7 January 2021

Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies

1 reference

7 January 2021

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

1 reference

7 January 2021

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

1 reference

7 January 2021

High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.

1 reference

7 January 2021

High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

1 reference

7 January 2021

1 reference

7 January 2021

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

1 reference

7 January 2021

Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Stu

1 reference

7 January 2021

Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia

1 reference

7 January 2021

Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma

1 reference

7 January 2021

1 reference

7 January 2021

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

1 reference

7 January 2021

Haematopoietic abnormalities after autologous stem cell transplantation in lymphoma patients

1 reference

7 January 2021

Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir

1 reference

7 January 2021

Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation

1 reference

7 January 2021

Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.

1 reference

7 January 2021

Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status

1 reference

7 January 2021

Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma

1 reference

7 January 2021

Radioimmunotherapy and secondary leukemia: a case report.

1 reference

7 January 2021

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

1 reference

7 January 2021

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

7 January 2021

High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologo

1 reference

7 January 2021

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

1 reference

7 January 2021

Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells

1 reference

7 January 2021

Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer

1 reference

7 January 2021

Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma

1 reference

7 January 2021

Identifiers

DOI

10.1002/CNCR.26182

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21567384 AND SRC:MED&resulttype=core&format=json

31 January 2020

1 reference